product name Tetrabenazine (Xenazine)
Description: Tetrabenazine is an agent for the symptomatic treatment of hyperkinetic movement disorder. FDA approved the use of tetrabenazine to treat chorea associated with Huntingtons disease (HD) On August 15, 2008, which is the first in the US. The precise mechanism of action of tetrabenazine is unknown. The antichorea effect is believed to be related to its effect as a reversible depletory of monoamines (such as dopamine, serotonin, norepinephrine and histamine)from nerve terminals)
References: Neurology. 1997 Feb;48(2):358-62; Ann Pharmacother. 2011 Apr;45(4):525-31.
317.42
Formula
C19H27NO3
CAS No.
58-46-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 58 mg/mL (182.7 mM)
Water: <1 mg/mL
Ethanol: 32 mg/mL (100.8 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References |
